Dubai Health Authority, Dubai, UAE
Emirates Health Economics Society, Dubai, UAE.
BMJ Open. 2024 Nov 4;14(11):e090344. doi: 10.1136/bmjopen-2024-090344.
In the evolving healthcare landscape of the United Arab Emirates (UAE), establishing cost-effectiveness thresholds (CETs) is pivotal to informing decision-makers about the value of health technologies.
This study aimed to establish CETs for the UAE that harmonise with international standards while reflecting the nation's unique healthcare needs and economic context.
United Arab Emirates.
A multitiered methodology was employed, involving a literature review, a panel of national experts and workshops with key stakeholders, including healthcare providers, government health departments and healthcare payers. The panel and workshops were integral in assessing global CET practices and their applicability to the UAE providing a preliminary framework for CET in the UAE. Structured voting sessions were then conducted allowing voting on crucial aspects of CET to determine the baseline threshold, multipliers for severity, rarity and health gain, and methodologies for quantifying disease severity.
CETs were linked to the economic status of the UAE, with a baseline threshold of 0.75 times the gross domestic product per capita for one quality-adjusted life year gained. A multiplier system was introduced to reflect societal views on disease severity, disease rarity and the relative health benefit of health technologies. Based on the voting results, disease rarity was deemed the most crucial factor, receiving a maximum multiplier of 3X, while severity and health gain were assigned a maximum of 2X. The multiplier values for both disease severity and relative health gain would be determined on a continuous scale. The proportional or relative shortfall method would be used to assess disease severity.
The proposed CET framework for the UAE will be dependent on local generation of cost-effectiveness evidence. Periodic review of CETs based on initial experiences ensures the responsiveness of policymakers to the changing healthcare and economic environment.
在阿联酋不断发展的医疗保健环境中,确定成本效益阈值(CET)对于向决策者提供有关卫生技术价值的信息至关重要。
本研究旨在为阿联酋建立与国际标准相协调的 CET,同时反映该国独特的医疗保健需求和经济背景。
阿拉伯联合酋长国。
采用多层次方法,包括文献回顾、国家专家小组以及与医疗保健提供者、政府卫生部门和医疗保健支付方等主要利益相关方的研讨会。该小组和研讨会对于评估全球 CET 实践及其在阿联酋的适用性至关重要,为阿联酋的 CET 提供了初步框架。然后进行了结构化投票会议,允许对 CET 的关键方面进行投票,以确定基准阈值、严重程度、罕见性和健康收益的乘数以及量化疾病严重程度的方法。
CET 与阿联酋的经济状况相关联,一个质量调整生命年获得的基准阈值为人均国内生产总值的 0.75 倍。引入了一个乘数系统,以反映社会对疾病严重程度、疾病罕见性和卫生技术相对健康效益的看法。根据投票结果,疾病罕见性被认为是最重要的因素,获得了 3 倍的最大乘数,而严重程度和健康收益则被分配了 2 倍的最大乘数。疾病严重程度和相对健康收益的乘数值将在连续范围内确定。将使用比例或相对不足方法来评估疾病严重程度。
阿联酋的拟议 CET 框架将取决于当地成本效益证据的生成。根据初始经验定期审查 CET,可确保决策者对不断变化的医疗保健和经济环境做出反应。